sulfatase

Estrone sulfate sodium (17β-Estrone 3-sulfate) is an endogenous steroid and an estrogen ester that is biologically inactive. It is converted by steroid sulfatase into estrone . Estrone sulfate sodium has been investigated as a ligand for targeting organic anion transporting polypeptides f

Steroid sulfatase-IN-9 (compound 54E) is a steroid sulfatase inhibitor with an inhibition rate of 87.03% at 10 μM. It shows no toxic effects on zebrafish larvae.

Steroid sulfatase-IN-10 (Example 216) is a potent inhibitor of steroid sulfatase, with an IC50 range of 0.03-0.27 µM. It is applicable in research on inflammatory diseases such as rheumatoid arthritis, type 1 and type 2 diabetes, and systemic lupus erythematosus.

Steroid sulfatase-IN-11 is an inhibitor of the steroid sulfatase enzyme (Steroid Sulfatase), effectively reducing the enzyme's ability to hydrolyze steroid sulfates. It is applicable for research in hormone-dependent cancers.

Steroid sulfatase-IN-2 is an active inhibitor of steroid sulfatase (STS), demonstrating an IC50 value of 109.5 nM. Its potential application lies in hormone-dependent cancer research, specifically estrogen-dependent breast and endometrial cancer [1].

Steroid sulfatase-IN-3 (compound 1q) is a potent STS inhibitor with an IC50 value of 25.8 nM and exhibits antiproliferative effects against T-47D estrogen-dependent breast cancer cells, with an IC50 of 1.04 μM [1].

Steroid sulfatase-IN-1 is a highly potent and orally active inhibitor of the enzyme Steroid sulfatase, with an impressive IC50 value of 1.71 μM. This compound exhibits notable antitumor activity, achieving a TGI (tumor growth inhibition) of 51% in vivo, holding great promise in breast cancer research [1].

Steroid sulfatase/17β-HSD1-IN-1 is a highly effective inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activities, with an IC50 value of 28 nM against cellular human steroid sulfatase. This compound holds significant potential for investigating estrogen-dependent diseases [1].

Steroid sulfatase/17β-HSD1-IN-4 (compound 37) is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). Steroid sulfatase/17β-HSD1-IN-4 irreversibly inhibits hSTS activity (IC50= 63 nM) and has research value in endometriosis and other estrogen-dependent diseases.

Steroid sulfatase/17β-HSD1-IN-3 (compound 19) is a dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 [17β-HSD1], useful in studying endometriosis and other estrogen-dependent diseases.

Steroid sulfatase-IN-4 (Compound 16) is an irreversible inhibitor of human steroid sulfatase (STS) with an IC50 of 25 nM, and can be used to study endometriosis.

Steroid sulfatase-IN-7 is an irreversible inhibitor of steroid sulfatase (STS) with an IC50 of 0.05 nM against human placental STS, making it suitable for cancer research applications [1].

Steroid Sulfatase-IN-6 (Compound 10c) serves as an irreversible steroid sulfatase (STS) inhibitor, exhibiting a K i value of 0.4 nM against human placenta STS, and is applicable in tumor disease research [1].

Steroid sulfatase-IN-5 (compound 10b) is an effective steroid sulfatase (STS) inhibitor with an IC50 of 0.32 nM that suppresses T-47D breast cancer cell proliferation, exhibiting an IC50 of 35.7 μM, and is utilized in breast cancer research [1].

Steroid sulfatase/17β-HSD1-IN-5 is an irreversible inhibitor of steroid sulfatase (STS) and a reversible, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), with IC50 values of 43 nM for 17β-HSD1 and 6.2 μM for 17β-HSD2. This compound is utilized in research related to metabolic diseases, particularly endometriosis [1].

Sulfatase from Patella vulgata (keyhole limpet) (EC 3.1.6.1) is an esterase enzyme that catalyzes the hydrolysis of sulfate esters. Together with sulfotransferase, sulfatase forms the primary catalytic mechanism for the synthesis and hydrolysis of sulfate esters.

Sulfatase, Abalone (EC 3.1.6.1), is an enzyme belonging to the esterases class, catalyzing the hydrolysis of sulfate esters. Together with sulfonyl transferase, sulfatase forms the primary catalytic mechanism for the synthesis and hydrolysis of sulfate esters.

2-O-Sulfatase [Flavobacterium heparinum] acts on the terminal 2-O-sulfate esters of unsaturated disaccharides and oligosaccharides resulting from the breakdown of sulfated glycosaminoglycans.

Steroid sulfatase-IN-8 (7), a potent STS inhibitor, exhibits an IC50 of 1 nM in PM and 0.025 nM in JEG-3, respectively [1].

N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential universal biomarker for several malignant tumors, including lung cancer, breast cancer, and head and neck cancer. Insufficient activity of N-Acetylgalactosamine-6-Sulfatase can lead to mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. This enzyme is utilized in research related to MPS IVA and cancer.

Estradiol 3-sulfamate (BLE 00084) is an orally active and highly potent steroidal estrone sulfatase (ES) inhibitor.Estradiol 3-sulfamate has a K(i) value of 73 nM for ES in human placental microsomes and can be used in the study of breast cancer.

Irosustat (667-Coumate) is a potent steroid sulfatase inhibitor, with an IC50 of 8 nM, and exhibits anti-breast cancer activity.

Elosulfase alfa (BMN 110), a recombinant human N-acetylgalactosamine-6-sulfatase (GALNS), serves as enzyme replacement therapy for mucopolysaccharidosis IVA (MPS IVA), commonly referred to as Morquio A syndrome [1].